RYBREVANT: payments to doctors
Payments that named RYBREVANT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $11.1M
- Providers
- 12,905
- Transactions
- 40,769
- Average per transaction
- $273
The per-transaction average — $273 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,905 providers the average total is $861, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $10,347,378 | 93.1% |
| Janssen Scientific Affairs, LLC | $623,808 | 5.6% |
| Janssen Global Services, LLC | $144,981 | 1.3% |
| Janssen Research & Development, LLC | $15 | 0.0% |